bebt-109
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 27, 2020 (NCT06001671)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06514027 | Phase 2 | Jul 31, 2024 | Guangzhou BeBetter Medicine Technology Co, LTD, Sun Yat-Sen University |
| NCT06706713 | Phase 2 | Apr 15, 2022 | Central South University, Guangzhou BeBetter Medicine Technology Co, LTD, Shantou University |
| NCT06001671 | Phase 1 | Oct 27, 2020 | Central South University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Guangzhou BeBetter Medicine Technology Co, LTD | For profit | 2 | 2 | 1 | 2022 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1